IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-32149-8.html
   My bibliography  Save this article

Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses

Author

Listed:
  • Norbert Pardi

    (University of Pennsylvania)

  • Juan Manuel Carreño

    (Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai)

  • George O’Dell

    (Icahn School of Medicine at Mount Sinai)

  • Jessica Tan

    (Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai)

  • Csaba Bajusz

    (University of Pennsylvania
    Institute of Genetics, Biological Research Centre)

  • Hiromi Muramatsu

    (University of Pennsylvania)

  • Willemijn Rijnink

    (Icahn School of Medicine at Mount Sinai)

  • Shirin Strohmeier

    (Icahn School of Medicine at Mount Sinai)

  • Madhumathi Loganathan

    (Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai)

  • Dominika Bielak

    (Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai)

  • Molly M. H. Sung

    (Acuitas Therapeutics)

  • Ying K. Tam

    (Acuitas Therapeutics)

  • Florian Krammer

    (Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai)

  • Meagan McMahon

    (Icahn School of Medicine at Mount Sinai)

Abstract

Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high capacity for rapid development. Generation of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is a necessity for reducing influenza-associated morbidity and mortality. Here we focus on the development of a universal influenza B virus vaccine based on the lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform. We evaluate vaccine candidates based on different target antigens that afford protection against challenge with ancestral and recent influenza B viruses from both antigenic lineages. A pentavalent vaccine combining all tested antigens protects mice from morbidity at a very low dose of 50 ng per antigen after a single vaccination. These findings support the further advancement of nucleoside-modified mRNA-LNPs expressing multiple conserved antigens as universal influenza virus vaccine candidates.

Suggested Citation

  • Norbert Pardi & Juan Manuel Carreño & George O’Dell & Jessica Tan & Csaba Bajusz & Hiromi Muramatsu & Willemijn Rijnink & Shirin Strohmeier & Madhumathi Loganathan & Dominika Bielak & Molly M. H. Sung, 2022. "Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32149-8
    DOI: 10.1038/s41467-022-32149-8
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-32149-8
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-32149-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Tejas Menon & Patricia T. Illing & Priyanka Chaurasia & Hayley A. McQuilten & Chloe Shepherd & Louise C. Rowntree & Jan Petersen & Dene R. Littler & Grace Khuu & Ziyi Huang & Lilith F. Allen & Steve R, 2024. "CD8+ T-cell responses towards conserved influenza B virus epitopes across anatomical sites and age," Nature Communications, Nature, vol. 15(1), pages 1-21, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32149-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.